Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy.
There is evidence indicating that resistance to some chemotherapy drugs is related to enhanced repair of DNA lesions. Microsatellite instability (MSI) and loss of heterozy-gosity (LOH) reflect genetic instability and are associated with specific DNA repair pathways. Despite the strong implication of genetic instability in breast cancer its association with chemotherapy is unknown. Thus, we analyzed microsatellite alterations with 12 markers in locally advanced breast carcinomas in relation to neoadjuvant epirubicin-cyclophosphamide-containing chemotherapy (FEC-100) and compared it to a docetaxol-based (Tax-Epi) regimen. Samples were obtained before, during and after treatments. In pre-treated samples, MSI was detected only in 2 cases (7%) whereas LOH was found in 23 of the 34 (68%) carcinomas including 10 belonging to the FEC-100 group and 13 to Tax-Epi one. LOH frequency decreased from the first course of both regimens, but differences between the patterns of LOH during treatment were found. Persistent LOH was more frequent in FEC-100 group (71% vs. 41%) that was detected only in biopsies belonging to non-responder patients. Persistent LOH were clustered at particular loci located at regions containing common fragile sites (FHIT and FRA6E). Analysis of baseline LOH with 6 markers located at 3p indicates discontinuous patterns reflecting double-strand break (DSB) lesions. These results agree with a drug-dependent link between genetic instability and chemoresistance and show that FEC-100 treatment is associated with DSB accumulation manifested as LOH in tumor cells resistant to chemotherapy in breast carcinoma.
Oudin
Claire
C
Laboratory of Molecular Genetics, Centre Georges François Leclerc, INSERM U-517, Dijon, France.
Bonnetain
Frank
F
Boidot
Romain
R
Végran
Frédérique
F
Soubeyrand
Marie-Sophie
MS
Arnould
Laurent
L
Riedinger
Jean-Marc
JM
Lizard-Nacol
Sarab
S
D001483:Base Sequence; D001706:Biopsy; D001943:Breast Neoplasms / Q000235:genetics*; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D002874:Chromosome Mapping; D002875:Chromosomes / Q000187:drug effects; D004247:DNA / Q000737:chemistry; D004249:DNA Damage; D004260:DNA Repair; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D019656:Loss of Heterozygosity; D018895:Microsatellite Repeats / Q000235:genetics*; D008969:Molecular Sequence Data
D004247:DNA